{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:04:11Z","timestamp":1773234251295,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ophtha.2008.08.006","type":"journal-article","created":{"date-parts":[[2008,10,19]],"date-time":"2008-10-19T04:08:07Z","timestamp":1224389287000},"page":"2282-2285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Diplopia, Blepharoptosis, and Ophthalmoplegia and 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Use"],"prefix":"10.1016","volume":"115","author":[{"given":"F.W.","family":"Fraunfelder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda B.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2008.08.006_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results","volume":"151","author":"Bradford","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ophtha.2008.08.006_bib2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2008.08.006_bib3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.iop.0000217573.90522.48","article-title":"Unrecognized side effect of statin treatment: unilateral blepharoptosis","volume":"22","author":"Ertas","year":"2006","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2008.08.006_bib4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/01.smj.0000170731.44173.34","article-title":"Rhabdomyolysis from simvastatin triggered by infection and muscle exertion","volume":"98","author":"Finsterer","year":"2005","journal-title":"South Med J"},{"key":"10.1016\/j.ophtha.2008.08.006_bib5","first-page":"427","article-title":"Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia","volume":"118","author":"Negevesky","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2008.08.006_bib6","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1371\/journal.pmed.0020123","article-title":"National trends in statin use by coronary heart disease risk category","volume":"2","author":"Ma","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.ophtha.2008.08.006_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","article-title":"Harmonisation in pharmacovigilance","volume":"10","author":"Edwards","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.ophtha.2008.08.006_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/108076804773710858","article-title":"Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors","volume":"20","author":"Fraunfelder","year":"2004","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2008.08.006_bib9","first-page":"824","article-title":"Drug-Induced Ocular Side Effects","author":"Fraunfelder","year":"2001"},{"key":"10.1016\/j.ophtha.2008.08.006_bib10","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ophtha.2008.08.006_bib11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5694\/j.1326-5377.2001.tb143683.x","article-title":"Statin-associated myopathy","volume":"175","author":"Hamilton-Craig","year":"2001","journal-title":"Med J Aust"},{"key":"10.1016\/j.ophtha.2008.08.006_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.ophtha.2008.08.006_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2008.08.006_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00007611-199807000-00013","article-title":"Peripheral neuropathy and lipid-lowering therapy","volume":"91","author":"Ziajka","year":"1998","journal-title":"South Med J"},{"key":"10.1016\/j.ophtha.2008.08.006_bib15","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ophtha.2008.08.006_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1742-7843.2006.pto_193.x","article-title":"Muscle symptoms associated with statins: a series of twenty patients","volume":"98","author":"Soininen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642008007458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642008007458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:56:52Z","timestamp":1758981412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642008007458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0161642008007458"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2008.08.006","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diplopia, Blepharoptosis, and Ophthalmoplegia and 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Use","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2008.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}